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RNA helicases are a large family of proteins that rearrange RNA structures and remodel ribonucleic
protein complexes using energy derived from hydrolysis of nucleotide triphosphates. They have been
shown to participate in every step of RNA metabolism. In the past decade, an increasing number of
helicases were shown to promote or inhibit the replication of different viruses, including human
immunodeﬁciency virus type 1. Among these helicases, the DEAD-box RNA helicase DDX17 was recently
reported to modulate HIV-1 RNA stability and export. In this study, we further show that the helicase
activity of DDX17 is required for the production of infectious HIV-1 particles. Over expression of the
DDX17 mutant DQAD in HEK293 cells reduces the amount of packaged viral genomic RNA and
diminishes HIV-1 Gag-Pol frameshift. Altogether, these data demonstrate that DDX17 promotes the
production of HIV-1 infectious particles by modulating HIV-1 RNA metabolism.
& 2013 Elsevier Inc. All rights reserved.Introduction
RNA helicases are a large family of proteins that are involved in
virtually all the steps of RNA metabolism (Cordin et al., 2006;
Linder and Jankowsky, 2011). They utilize the energy derived from
nucleotide triphosphates (NTPs) hydrolysis to unwind nucleic
acids and remodel ribonucleic protein (RNP) complexes (Tanner
and Linder, 2001). RNA helicases are classiﬁed into ﬁve super
families (SF1 to SF5) on the basis of their conserved motifs. They
are prevalent in eukaryotes, prokaryotes and viruses (Kwong et al.,
2005; Singleton et al., 2007). The SF2 has the most members, and
includes the DEAD-box helicases that harbor the Asp-Glu-Ala-Asp
signature motif (Linder et al., 1989). In humans, malfunction of
helicases causes various types of cancers (Clark et al., 2008; Fuller-
Pace and Moore, 2011; Rezazadeh, 2012).
Viruses need helicases to successfully replicate their nucleic
acid genome. Some viruses carry their own helicase, such as
Hepatitis C virus that encodes the NS3 protein (Kanai et al.,
1995; Kim et al., 1995), while others need to hijack cellular ones
to assist viral replication. Human immunodeﬁciency virus type 1
(HIV-1), like all retroviruses, does not encode a viral helicase. Over
the past decade, many cellular RNA helicases have been reportedll rights reserved.
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include RNA helicase A (RHA), Moloney leukemia virus 10 (MOV10),
XPB/XPD, Ku70/Ku80, Werner syndrome (WRN) helicase, DDX1,
DDX3, DDX17, DDX24, Upf1 and DHX30 (reviewed in (Jeang and
Yedavalli, 2006; Lorgeoux et al., 2012; Ranji and Boris-Lawrie, 2010;
Steimer and Klostermeier, 2012)). RHA promotes HIV-1 reverse
transcription, transcription and translation (Bolinger et al., 2010;
Fujii et al., 2001; Roy et al., 2006; Xing et al., 2011). MOV10 inhibits
viral reverse transcription (Burdick et al., 2010; Furtak et al., 2010).
DDX1, DDX3 and DDX17 promote Rev-dependent HIV-1 RNA export
(Fang et al., 2004; Naji et al., 2012; Yedavalli et al., 2004). In addition
to its role in HIV-1 RNA export, DDX3 also enhances HIV-1
translation (Geissler et al., 2012; Lai et al., 2010, 2008; Soto-Rifo
et al., 2012, 2013). Upf1 and DDX17 are involved in HIV-1 RNA
degradation (Ajamian et al., 2008; Zhu et al., 2011). DDX24
promotes HIV-1 RNA packaging (Ma et al., 2008), while DHX30
was reported to inhibit this step (Zhou et al., 2008). Recently,
SLFN11 was shown to inhibit HIV-1 translation in a codon-usage-
dependent manner (Li et al., 2012), adding a new layer of viral RNA
regulation by cellular helicases.
DDX17, also known as RH70, has two isoforms, p72 and p82, as
a result of alternative translation of its messenger RNA (mRNA)
(Uhlmann-Schifﬂer et al., 2002). DDX17 can form heterodimers
with its paralog DDX5 (Ogilvie et al., 2003) and is involved in
multiple aspects of RNA metabolism. Through interaction with
other cellular factors, including HDAC1 (Wilson et al., 2004),
estrogen receptor alpha (Wortham et al., 2009) and U1snRNP
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splicing. Its dysfunction can lead to cancer development
(Dardenne et al., 2012; Honig et al., 2002; Shin et al., 2007).
Recently, DDX17 was reported to act as a co-factor of the zinc
ﬁnger antiviral protein ZAP (Chen et al., 2008), which is involved
in the degradation of the multiply spliced HIV-1 mRNA (Zhu et al.,
2011). Another study by Naji et al., (2012) showed that DDX17
associates with HIV-1 Rev protein, and promotes the nuclear
export of HIV-1 transcripts . We now further show that DDX17
affects the production of infectious HIV-1 particles. Knockdown
and over expression of DDX17 change the ratios of unspliced vs
spliced HIV-1 RNA. Furthermore, over expression of the DDX17
DQAD mutant leads to a dramatic decrease in the amount of
packaged viral RNA. Moreover, DDX17 is required for efﬁcient Gag
processing through its effect on HIV-1 Gag-Pol frameshift. Alto-
gether, our results demonstrate new roles for DDX17 in promoting
the production of infectious HIV-1 particles through regulating
HIV-1 Gag-Pol frameshift and genomic RNA packaging.Materials and methods
Plasmid DNA, viruses and antibodies
The cDNA clone of DDX17 gene was purchased from ATCC
(MGC-2030). Short and long isoforms of DDX17 cDNA were
ampliﬁed by PCR and a Flag tag was added at the N terminus using
primer pairs DDX17-SS/DDX17-A, DDX17-SL/DDX17-A, respectively
(Table 1). The PCR products were digested with BamHI and MulI and
inserted into the pRetroX-Tight-Pur retroviral vector (Clontech) to
create DNA plasmids Tet-DDX17S and Tet-DDX17L that are expressed
in response to doxycyclin. DDX17 mutants were generated by site-
directed mutagenesis using primers DQAD-S and DQAD-A (Table 1).
DDX5 cDNA clone was kindly provided by Dr Stahl (Rossler et al.,
2000). The infectious HIV-1 proviral DNA clone NL4-3 was obtained
from the NIH AIDS Research and Reference Reagent Program. Tat
plasmid was kindly provided by Dr. Gatignol (Gatignol et al., 1991).
The frameshift luciferase reporter constructs FS (0) and FS (-1) were
previously described (Grentzmann et al., 1998) and provided by
Dr. Brakier-Gingras. HIV-1 viruses were generated by transfecting
HEK293T cells with the proviral DNA clone NL4-3, using lipofecta-
mine 2000 (Invitrogen) according to the manufacturer's instruction.
When indicated, the vesicular stomatitis virus (VSV) glycoprotein
(G) was used to pseudotype HIV-1 particles.
Anti-Flag and anti-tubulin antibodies were purchased from Sigma;
anti-HIV-1 p24 antibody from ID Lab Inc.; anti-DDX5 and anti-DDX17
antibodies were purchased from Abnova (H00001655-B01) and
Novus Biological (NB200–352), respectively.
Cell culture and transfections
TZM-bl, HeLa and HEK293 cells were grown at 37 1C with 5%
CO2 in Dulbecco's Modiﬁed Eagle Medium (DMEM) supplementedTable 1
List of primers used.
Primer Sequence
DDX17-SS 5′-GCACGGATCCATG
DDX17-SL 5′-GCACGGATCCATG
DDX17-A 5′-GCAGACGCGTCAT
DQAD-S 5′-CTTGTATTGGACCA
DQAD-L 5′-GCATTCTGTCAGC
FP 5′-AGTAAAGCCAGAG
FL 5′-TACCTCTTGTGAAG
RP1 5′-ATTGGTATTAGTAT
RP2 5′-GCCACCCATCTTATwith 10% Fetal Bovine Serum (FBS). Plasmids and short interfering
RNA (siRNA) were transfected into cells using lipofectamine2000
according to the manufacturer's protocol.
Knockdown of DDX5 and DDX17 in HeLa cells
siRNA oligonucleotides targeting DDX17 (nt 1694–1713) were
purchased from Qiagen (5′-AAT ACA CCT ATG GTC AAG GCA-3′)
(Cat. no. 1027423). siRNAs oligonucleotides targeting DDX5 and
the DDX5-DDX17 subfamily were previously described (Jalal et al.,
2007). Control siRNA was purchased from Qiagen (Cat. No.
1027281). shRNA targeting DDX17 (nt 1525–1545) was purchased
from SIGMA (5′-CCC AAT CTG ATG TAT CAG GAT-3′). Control shRNA
was also purchased form SIGMA (Cat. No. SHC016). HeLa cells
(2105 per well) were seeded in 6-well plates 1 day before siRNA
transfection. DDX5 and DDX17 were either knocked down indivi-
dually, or simultaneously. 10 nM of each siRNA was used in
transfection. After two sequential siRNA transfections, the cells
were transfected with HIV-1 NL4-3 DNA. Cells and supernatants
were harvested 40 h post HIV-1 NL4-3 transfection. Protein levels
were analyzed by Western blotting, virus production was assessed
by infecting the TZM-bl indicator cells.
DDX17 overexpression in HEK293 cells
HEK293 cells (5105 per well) were seeded in 6-well plates
1 day before transfection. 500 ng of DDX17 DNA constructs were
co-transfected with 100 ng Tet-ON plasmid and 100 ng HIV-1 NL4-3.
Cells were washed in 1phosphate buffered saline the next day and
fresh DMEM containing 100 ng/mL doxycyclin was added to induce
DDX17 expression. Cells and supernatants were harvested 40 h post
HIV-1 NL4-3 transfection. Protein levels were analyzed by Western
blotting and virus production was measured by infecting TZM-bl
indicator cells.
Viral RNA analysis
Levels of viral RNA in cells were assessed by Northern blots as
previously described (Roy et al., 2006; Zhou et al., 2008) (and
RT-PCR followed by Southern blot, described below). Brieﬂy,
transfected cells were washed with 1 phosphate buffered saline
and lysed in Trizol (Invitrogen). RNA was extracted according to
the manufacturer's instructions. Northern blot analysis was per-
formed as previously described (Zhou et al., 2008). Brieﬂy, RNA
was subjected to electrophoresis on a 1% denaturing agarose gel.
RNA was transferred to nylon membranes (GE Healthcare UK
Limited) and incubated with [α-32P] labeled HIV-1 DNA. Mem-
branes were washed with 1 saline-sodium citrate (SSC) buffer
containing 0.1% SDS and viral RNA signals were visualized by
exposure to X-ray ﬁlms.
Levels of virion-associated viral RNA and total viral RNA were
determined by RT-PCR followed by Southern blots. RNA was ﬁrstGATTACAAGGATGACGACGATAAGCGCGGAGGAGGCTTTGGGGAC-3′
GATTACAAGGATGACGACGATAAGCCCACCGGCTTTGTAGCCCCG-3′
TTACGTGAAGGAGGAGG-3′
AGCTGACAGAATGC-3′
TTGGTCCAATACAAG-3′
GAGATCTCTCG-3′
CTTGCTCGGCTCT-3′
CAATCTTCAAATC-3′
AGCAAAATCC-3′
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DNase I (Amp Grade) digestion at room temperature for 15 min to
remove any contaminating plasmid DNA. DNase I (Amp Grade)
was inactivated at 65 1C for 10 min. The effectiveness of DNase I
(Amp Grade) treatment was tested by amplifying the treated RNA
samples by PCR with the primers FP and FL (Table 1). This primer
pair ampliﬁes HIV-1 cDNA sequence spanning nucleotides 665 to
1729. Reverse primers RP1 and RP2 were used for the ampliﬁca-
tion of singly spliced and multiply spliced HIV-1 transcripts,
respectively, and were previously described (Zhu et al., 2011).
RNA equivalent to 25 ng of p24 was reverse transcribed and
ampliﬁed with the primers FP and FL or RP1 or RP2, using the
Titan One Tube RT-PCR System (Roche) according to the manu-
facturer's instruction and 20 PCR cycles (Reverse transcription at
50 1C for 1 h, followed by reverse transcriptase inactivation at
94 1C for 5 min; PCR: denaturation at 95 1C for 30 s, annealing at
45 1C for 30 s and elongation at 68 1C for 2 min). RT-PCR products
were subjected to electrophoresis on a 1% agarose gel (0.5 Tris
Borate EDTA) for 2 h at 60 V. The gel was treated in 0.2 M HCl for
13 min, NaOH 0.5 M for 30 min, NaCl 0.5 M (pH 7.5) for 30 min and
double-distilled H2O for 10 min. The DNA was transferred to a
nylon Hybond-N membrane (GE Healthcare UK Limited) with 10
SSC overnight. The next day, the membrane was washed in 6
SSC for 5 min at room temperature and RNA was ﬁxed by UV
cross-linking. Next, the membrane was incubated with 10 mL
pre-hybridization buffer (Ambion) at 42 1C for 2 h followed by
overnight hybridization at 42 1C with a [α-32P] labeled HIV-1
probe. The next day, the membrane was washed with 1 SSC,
0.1% SDS at room temperature for 15 min. Signals were quantiﬁed
using a phosphoscreen and the Phosphoimager (Amersham).
Virus production assays
The amount of infectious viruses in culture supernatants was
determined by infecting the TZM-bl cells. Cells were seeded in
24-well plate at a density of 4104 cells per well 1 day before
infection. 50 μL of supernatant from transfected cells were used to
infect TZM-bl cells. Forty-eight hours after infection, cells were
lysed in 1 passive lysis buffer (Promega), and levels of ﬁreﬂy
luciferase activity in the cell lysates were measured using the
Luciferase Assay kit and the Glomax luminometer (Promega).
Virus production was determined by measuring viral reverse
transcriptase (RT) activity in the supernatants (Lu et al., 2011).Results
Knockdown of DDX17 but not DDX5 reduces HIV-1 production and
infectivity
DDX17 was recently identiﬁed as a co-factor of ZAP that causes
the degradation of HIV-1 multiple spliced mRNAs (Chen et al.,
2008). DDX17 was also reported to associate with Rev, and
promote the export of incompletely spliced HIV-1 RNAs from the
nucleus to the cytoplasm (Naji et al., 2012). To determine the effect
of DDX17 on HIV-1 production, we silenced DDX17 in HeLa cells
using siRNAs, followed by transfection of HIV-1 NL4-3 DNA
(Fig. 1A). We observed a two-fold decrease in the amount of viral
particles upon DDX17 knockdown (Fig. 1B), which correlates with
a diminution of the viral p24 levels in the supernatant (Fig. 1C).
Furthermore, quantiﬁcation of infectious viruses by infecting TZM-
bl indicator cells revealed a four-fold decrease (Fig. 1D). Therefore,
the infectivity of viral particles is decreased by two-fold. Together
with the work from other studies, our data suggest that DDX17
affects the amount and the quality of HIV-1 particles made. When
DDX5, a paralog of DDX17, was silenced, we observed a slightincrease in the amount of HIV-1 virions and no change in the
infectivity of HIV-1 particles (Fig. 1D). Interestingly, silencing
DDX5 moderately increased DDX17 expression (including both
the p72 and p82 isoforms) (Fig. 1A). This suggests that cells
compensate for the loss of DDX5 by increasing DDX17 expression,
as reported by others (Shin et al., 2007). Along this line, over
expression of DDX5 or DDX17 also moderately diminished the
level of DDX17 or DDX5 (Fig. S1), which further indicates the
mutual effects on their expressions. Knockdown of both DDX5 and
DDX17 severely diminished cell viability, thus was not tested on
HIV-1 production (data not shown). In order to conﬁrm the
observed inhibitory effect of DDX17 knockdown on HIV-1 produc-
tion, we utilized an shRNA to deplete endogenous DDX17 in HeLa
cells. A profound decrease in the generation of infectious HIV-1
particles was again observed (Fig. 1E). Collectively, we conclude
that DDX17 is required for HIV-1 production.
HIV-1 production is inhibited by DDX17 mutant carrying the mutated
DEAD box motif
As a typical RNA helicase, DDX17 carries seven conserved
motifs including the DEAD box that is critical for helicase activity
(Fig. 2A). To determine whether the helicase activity of DDX17 is
required for its effect on HIV-1 production, we mutated the DEAD
motif to DQAD in the context of both the long (p82) and short
(p72) forms of DDX17 (Fig. 2A). We then transfected HEK293 cells
with various DDX17 constructs and the HIV-1 proviral DNA NL4-3
(Fig. 2B), and analyzed viral particles released in the supernatant.
DDX17 DQAD (L) mutant expression led to a 3.5-fold decrease in
the amount of viral particles as being determined by measuring
viral reverse transcriptase activity in the supernatants (Fig. 2C).
We further determined the levels of infectious HIV-1 particles by
infecting the TZM-bl indicator cells, and observed that the DQAD
(L) mutant caused a 10-fold reduction (Fig. 2E). Considering the
3.5-fold decrease in the viral RT level (Fig. 2C) and the diminution
in p24 found in the supernatant (Fig. 2D), we conclude that DQAD
(L) decreases the infectivity of HIV-1 particles by three-fold. For
the DQAD (S) mutant, we observed a 50% decrease in the viral RT
(Fig. 2C) and a 70% decrease in virus production (Fig. 2E). We also
ectopically expressed DDX17 and its DQAD mutants in HeLa cells
and observed a more than ﬁve-fold reduction in the production of
infectious HIV-1 particles as a result of DQAD expression (Fig. S2).
Taken together, these results suggest that the DQAD mutant of
DDX17 impairs the production of infectious HIV-1 particles. Con-
sidering the existence of endogenous DDX17 when DQAD mutant
is ectopically expressed, we conclude that this mutant acts in a
dominant negative fashion to prevent the endogenous DDX17
from promoting HIV-1 production.
DDX17 expression increases HIV-1 genomic RNA packaging
To understand how the DDX17 DQAD mutant reduces the
production of infectious HIV-1 particles, we ﬁrst measured the
levels of viral RNA associated with HIV-1 particles. We thus
transfected 293 cells with the DDX17 and HIV-1 NL4-3 DNA clones.
Viral particles from culture supernatants were harvested 2 days
post transfection and amounts of particles were determined by
ELISA against HIV-1 p24. Viral RNA was ampliﬁed by RT-PCR and
further quantiﬁed in Southern blotting (Fig. 3). We observed that
the short isoform of wild-type DDX17 over expression led to a 40%
increase in the amount of RNA that is packaged into HIV-1
particles. In contrast, the DDX17 DQAD mutants resulted in a
dramatic 5- to 10-fold decrease in the amount of packaged HIV-1
genomic RNA (gRNA). The stronger inhibition of HIV-1 RNA
packaging by the longer DQAD mutant may result from its higher
expression level than the shorter DQAD mutant. Alternatively, the
Fig. 1. Effect of DDX5 and DDX17 knockdown on HIV-1 production. (A) HeLa cells (1.5105) were transfected with 0.1 μg HIV-1 NL4-3 DNA and 20 pmol/mL siRNAs
directed against DDX17 or DDX5. Levels of endogenous DDX5 and DDX17 were determined by Western blotting. (B) Culture supernatants were harvested 48 h post
transfection and the amounts of virus particles were determined by measuring viral reverse transcriptase activity. (C) Levels of viral particles in the culture supernatants
were analyzed by Western blotting with anti-HIV-1 p24 antibody. (D) Levels of infectious HIV-1 particles in the supernatants were determined by infecting the TZM-bl
indicator cells. (E) HeLa cells (1.5105) were transfected with 0.1 μg HIV-1 NL4-3 DNA and 1.0 μg shRNA directed against DDX17. Protein expression levels in cell lysate were
analyzed byWestern blotting with anti-DDX17 or DDX5 antibodies. Culture supernatants were harvested 48 h post-transfection and the levels of released viral particles were
analyzed by the Western blotting with anti-p24 antibody. The amounts of infectious virus particles were further determined by infecting the TZM-bl indicator cells ***
represents a P-valueo0.001, n¼6. The P value was calculated with reference to the control siRNA data. p82, DDX17 L (long) isoform; p72, DDX17 S (short) isoform;
p68, DDX5.
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which are absent in DDX17 short forms (p72) may be involved in
preventing HIV-1 RNA packaging. These results suggest that the
DQAD mutant impedes HIV-1 RNA packaging and thus reduces
virus infectivity.The DDX17 DQAD mutant disturbs the balance of the unspliced vs
spliced HIV-1 RNA pools
A decrease in the amount of packaged HIV-1 RNA can be the
result of multiple causes, including defects in viral RNA expression
Fig. 2. Effect of DDX17 overexpression on HIV-1 production.(A) Illustration of DDX17 DNA constructs. Conserved helicase Walker B motif, or DEAD-box, was mutated into
DQAD and inserted into both short and long isoforms of DDX17, DQAD (S) and DQAD (L). (B) HEK293 cells (5105) were transfected with 0.1 μg HIV-1 NL4-3 DNA and 0.5 μg
DDX17. Levels of DDX17 and its mutants in cell lysate were analyzed by Western blot using either anti-Flag or anti-DDX17 antibodies. (C) Levels of viral reverse transcriptase
activity in the culture supernatants. (D) The amounts of HIV-1 particles in the supernatants were determined by Western blotting using anti-HIV-1 p24 antibody. (E) Levels
of infectious HIV-1 particles were determined by infecting the TZM-bl indicator cells. Levels of luciferase activity reﬂect the relative infectiousness of the virus samples
tested. ** represents a P-valueo0.01, n¼3. p82, DDX17 L isoform; p72, DDX17 S isoform; Ctrl, control.
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Terminal Repeat (LTR) promoter activity by transfecting DDX17
DNA and Tat into the TZM-bl indicator cells that contain the HIV-1
LTR-luciferase reporter (Fig. 4A). We observed no detectable effect
of DDX17 on Tat-dependent HIV-1 transcription. Transfection of
40 ng HIV-1 Tat showed a further 10-fold increase in luciferase
activity, attesting that the assay was not saturated (data not
shown).
Recently, DDX17 was reported to act as a cofactor of ZAP and
contribute to the degradation of multiply spliced HIV-1 RNA (Zhu
et al., 2011). In addition, no noticeable effect was seen on the levels
of full length viral RNA upon silencing of ZAP (Zhu et al., 2011). In
another recent study, Naji et al. (2012) reported that DDX17
silencing led to a decrease in the levels of both multiply spliced
and unspliced HIV-1 RNAs . Naji et al. (2012) also reported that
DDX17 associates with the viral protein Rev to promote the export
of RRE-containing viral RNAs. To further determine the effect ofDDX17 on HIV-1 RNA expression, we transfected HEK293 cells
with DDX17 plasmids and HIV-1 NL4-3, and examined HIV-1 RNA
levels by Northern blot (Fig. 4C). We found that overexpression of
wild-type DDX17 led to a slight increase in HIV-1 full length RNA
while over expression of DDX17 DQAD mutants induced an
increase in HIV-1 multiply spliced mRNA species and a decrease
in HIV-1 full length RNA (Fig. 4C). To conﬁrm this observation, we
silenced DDX17 and DDX5 in HeLa cells and analyzed HIV-1 RNA
by Northern blot (Fig. 4B). We observed that silencing DDX17 led
to an increase in HIV-1 spliced transcripts and a decrease in the
viral full length RNA (Fig. 4B). Interestingly, DDX5 knockdown
displayed an opposite effect, as we observed an increase in HIV-1
full length RNA and a decrease in HIV-1 RNA spliced forms
(Fig. 4B). Consistent with the effect of DDX17 knockdown on viral
particles shown in Fig. 2C, this pattern can be explained by the fact
that the cells compensate for the loss of DDX5 by upregulating the
expression of DDX17.
Fig. 3. Effect of DDX17 on HIV-1 gRNA packaging. HEK293 cells (5105) were
transfected in 6-well plates with 0.5 μg DDX17 DNA and 0.1 μg HIV-1 NL4-3. Culture
supernatants were harvested 48 h post transfection and the amounts of particles
were quantiﬁed by ELISA against HIV-1 p24. Virus particles corresponding to 55 ng
of p24 were spun at 35,000 rpm for 1 h and RNA equivalent to 10 ng of p24 were
used for RT-PCR assay. RT-PCR products corresponding to 6 ng of p24 were
analyzed by Southern blot, and radioactive signal intensity was quantiﬁed by
Phosphoimager (Amersham). Results of one of the three independent transfection
experiments are shown. **Represents a P-valueo0.01.
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quantify their relative amounts, we analyzed viral transcripts by
RT-PCR followed by Southern blotting as described in (Zhu et al.,
2011) (Fig. 4D–F). We observed that over expression of DDX17
DQAD (L) led to a 3.5-fold increase in the amount of multiply
spliced RNAs, and up to a 50% decrease in the full length RNA
(Fig. 4D and E), which results in 6.5-fold increase for the multiply
spliced/full length HIV-1 RNA ratio (Fig. 4F). Over expression of
wild-type DDX17 had no signiﬁcant effect on the relative amounts
of different HIV-1 RNA species. Supporting the work from other
groups (Chen et al., 2008; Naji et al., 2012; Zhu et al., 2011), our
results suggest that DDX17 affects the balance of spliced and
unspliced HIV-1 RNA populations.
DDX17 modulates HIV-1 Gag processing
Expression of DDX17 DQAD mutant in HEK293 cells decreases
the amount of viral p24 in the supernatant (Fig. 1D). This defect
may result from diminished HIV-1 protein expression in cells. To
test this, we transfected HEK293 cells with DDX17 constructs and
HIV-1 NL4-3 DNA and analyzed viral protein expression by
Western blot (Fig. 5A). We observed that expression of DDX17
DQAD decreased the amount of viral p24. However, the level of
Pr55Gag was not affected, suggesting that the DDX17 mutant likely
inhibits Gag processing rather than impeding Gag production
(Fig. 5A). Similarly, DDX17 knockdown in HeLa cells reduced the
amount of viral p24 but not Pr55Gag, suggesting the same defect in
Gag cleavage (Fig. 5B).
HIV-1 genome encodes two polyproteins Pr160Gag-Pol and
gp160Env. While gp160Env precursor is cleaved in gp120 and
gp41 by the cellular protease Furin (Hallenberger et al., 1992),
the Gag-Pol polyprotein is self-cleaved by the viral protease (PR)
(Darke et al., 1988). HIV-1 Pol gene encodes the three viral
enzymes, including protease (PR), reverse transcriptase (RT) and
integrase (IN) among which PR is responsible for the processing of
Pr160Gag-Pol and Pr55Gag precursors. In order to assess the effect ofDDX17 on total Gag expression, we transfected HEK293 cells with
DDX17 DNA and treated the cells with 100 nM duranavir, an HIV-1
PR inhibitor, and assessed the levels of Pr160Gag-Pol and Pr55Gag in
the cell lysate (Fig. 5C). For wild-type DDX17, DRV treatment led to
the accumulation of Pr160Gag-Pol, as a result of HIV-1 PR-depen-
dent cleavage inhibition. No overall changes were observed for
total Gag levels upon wild-type DDX17 expression (Fig. 5C). Inter-
estingly, overexpression of DDX17 mutants led to a slight decrease
in the amount of Pr160Gag-Pol but no signiﬁcant effect on Pr55Gag
expression (Fig. 5C). In addition, as seen in Fig. 5A, p24 levels were
dramatically diminished upon the expression of both DQAD
(S) and DQAD (L) mutants. Our results suggest that the DDX17
DQAD mutant compromises Gag processing, and the decrease in
the overall amount of Gag-Pol products suggests a possible defect
in HIV-1 frameshift activity.
Effect of DDX17 on Gag-Pol frameshift
To regulate the ratio of Gag and Gag-Pol expression, HIV-1 has
evolved a slippery RNA sequence that causes -1 frameshift, which
allows producing HIV-1 enzymes (Jacks et al., 1988; Vaishnav and
Wong-Staal, 1991). Therefore, a decrease in HIV-1 frameshift
efﬁciency implies a defect in the production of viral enzymes,
including HIV-1 PR that is responsible for Gag cleavage, thus
reduces virus particle infectivity. To test this hypothesis, we used
two dual-luciferase reporter plasmids FS (0) and FS (−1) previously
described by Grentzmann to measure HIV-1 Gag-Pol frameshift
(Grentzmann et al., 1998) (Fig. 6A). We transfected HEK293 cells
with DDX17 DNA with either FS (0) or FS (−1) reporter and
quantiﬁed luciferase expression levels. We observed that over
expression of DDX17 DQAD mutant led to up to 40% decrease in
frameshift efﬁciency (Fig. 6B). No signiﬁcant effect was observed
for the wild type DDX17. These results suggest that the helicase
activity of DDX17 is involved in maintaining the proper ratio of
Gag/Pol gene expression required for optimal infectivity.Discussion
In this study, we found that DDX17 promotes HIV-1 particle
infectivity by modulating HIV-1 RNA packaging and Gag-Pol
frameshift. Viral RNA analysis also demonstrates that the over
expression of the helicase negative DDX17 DQAD mutant increases
the multiply spliced/unspliced HIV-1 RNA ratio by up to six-fold
(Fig. 4F). Recently, Chen et al., (2008) reported that the zinc ﬁnger
antiviral protein ZAP interacts with DDX17 that acts as a cofactor
to potentiate the activity of ZAP in inhibiting the replication of a
few viruses, including murine leukemia virus. The same group
also showed that ZAP targets HIV-1 multiply spliced mRNA to
exosomes for degradation (Zhu et al., 2011). The crystal structure
of the N-terminal domain of ZAP reveals the RNA binding region
that is likely involved in HIV-1 RNA recognition (Chen et al., 2012).
In addition to its role in ZAP-mediated degradation of multiply
spliced HIV-1 mRNA, DDX17 also has ZAP-independent functions
in HIV-1 replication. Naji et al. (2012) found that DDX17 interacts
with HIV-1 Rev and that DDX17 silencing reduced the amount of
viral transcripts and inhibited the export of both unspliced and
spliced HIV-1 mRNAs to the cytoplasm.
In our study, we also found that DDX17 silencing led to a
decrease in full length HIV-1 RNA (Fig. 4C). Interestingly, this
decrease in full length RNA correlates with an increase in multiply
spliced viral transcripts (Fig. 4). We propose that several mechan-
isms may account for the accumulation of multiply spliced HIV-1
RNA upon DDX17 silencing or DDX17 DQAD over expression. The
ﬁrst mechanism is simply the inefﬁcient ZAP-mediated degrada-
tion of HIV-1 multiply spliced RNA (Zhu et al., 2011). A second
Fig. 4. Effect of DDX17 on HIV-1 RNA expression. (A) HeLa TZM-bl cells (4104) were transfected in 24-well plates with 0.1 μg DDX17 DNA and either 10 ng of HIV-1 Tat or
10 ng cDNA3.1. Luciferase activity was measured 24 h post-transfection (n¼4). (B) HeLa cells (1.5105) were transfected with 0.1 μg HIV-1 NL4-3 DNA and 20 pmol/ml
siRNAs against DDX17 or DDX5. Cells were lysed in Trizol (Invitrogen) 48 h post transfection and HIV-1 RNA proﬁle was analyzed by Northern blot. (C) HEK293 cells (5105)
were transfected with 0.1 μg HIV-1 NL4-3 DNA and 0.5 μg DDX17. Cells were lysed in Trizol (Invitrogen) 48 h post-transfection and HIV-1 RNA proﬁle was analyzed by
Northern blot. (D) HIV-1 RNA samples from the co-transfected HEK293 cells were ﬁrst ampliﬁed by RT-PCR using different primer pairs, then subject to Southern blot
analysis. (E, F) Radioactive signals from the distinct viral RNA species were quantiﬁed from the Southern blot using phosphorescreen and Phosphoimager (Amersham) and
splicing ratios were calculated. FL, full length; SS, singly spliced; MS, multiply spliced.
R.-P. Lorgeoux et al. / Virology 443 (2013) 384–392390mechanism involves excessive splicing due to sequestration of
HIV-1 RNA in the nucleus, which leads to decreased amount of
unspliced viral mRNA and increased amount of multiply spliced
HIV-1 mRNAs. Lastly, DDX17 may directly modulate HIV-1 RNA
splicing, as previously reported for DDX17 to affect alternative
splicing of cellular genes (Honig et al., 2002). HIV-1 splicing is a
highly regulated process, which involves stem-loops regulatory
elements called splicing silencers and splicing enhancers and
generates more than 30 HIV-1 RNA species (Stoltzfus, 2009).
During splicing, RNA is remodeled in order to expose splicing
silencers and splicing enhancer stem-loops that act as dockingsites for distinct members of the spliceosome machinery, thereby
inﬂuencing exon deﬁnition (Chen and Manley, 2009; Stoltzfus,
2009). One hypothesis would be the involvement of DDX17 in
remodeling HIV-1 RNA structure, leading to a change in exon
deﬁnition, resulting in an increase of full length and a decrease in
spliced HIV-1 RNAs, as seen in Fig. 4. Generally, moderate effects
were seen for the over expression of wild type DDX17, which can
be due to the fact that endogenous levels are sufﬁciently high to
promote the production of infectious HIV-1 particles.
We found that expression of DDX17 mutants induce a dramatic
decrease in the amount of packaged gRNA (Fig. 3), which leads to
Fig. 5. DDX17 modulates HIV-1 Gag processing. (A) HEK293 cells (5105) were
transfected with 0.1 μg HIV-1 NL4-3 DNA and 0.5 μg DDX17. Protein expression
levels in cell lysate were analyzed by Western blot using anti-p24, anti-FLAG and
anti-tubulin antibodies. (B) HeLa cells (1.5105) were transfected with 0.1 μg HIV-
1 NL4-3 DNA and 20 pmol/mL siRNAs directed against DDX17 or DDX5. Protein
expression levels in cell lysate were analyzed by Western blot using anti-p24, anti-
DDX5, anti-DDX17 and anti-tubulin antibodies. (C) HEK293 cells (5105) were
transfected with 0.1 μg HIV-1 NL4-3 clone and 0.5 μg DDX17 DNA and treated with
100 nM protease inhibitor duranavir (DRV). Cells were lysed 48 h post-transfection
and protein levels were analyzed by Western blot using anti-p24 and anti-tubulin
antibodies.
Fig. 6. Effect of DDX17 on Gag-Pol frameshift. (A) Depiction of the HIV-1
frameshift dual-luciferase reporter constructs FS (0) and FS (-1), described in
(Grentzmann et al., 1998). (B) HEK293 cells (5105) were transfected with 0.5 μg
DDX17 DNA and 75 ng of either dual luciferase reporter FS(0) or FS (-1). FL/RL ratios
were calculated and the FL/RL FS(-1)/ FL/RL FS(0) was plotted to indicate frameshift
efﬁciency. **Represents a P-valueo0.01, n¼3. (C) Levels of the ectopically
expressed DDX17 and its DQAD mutants as determined by Western blotting.
R.-P. Lorgeoux et al. / Virology 443 (2013) 384–392 391the production of less infectious viral particles. Considering that
the amount of full-length HIV-1 RNA decreased by only two-fold in
the cells for DQAD (L), we conclude that the packaging of gRNA
was diminished by ﬁve-fold. Similarly, we observed a 1.5 fold
decrease in full length HIV-1 RNA for DQAD (S), but a 3.5-fold
diminution in packaged gRNA (Fig. 3). This data suggests that the
helicase activity of DDX17 is necessary to promote HIV-1 gRNA
packaging. HIV-1 RNA packaging is a complicated process that
involves interactions of cellular and viral proteins with speciﬁc
viral RNA motifs. HIV-1 5′UTR contains a number of stem-loop (SL)
structures that act as regulatory sites for multiple processes,
including splicing and packaging. Being a RNA helicase, it is
possible that DDX17 remodels the viral RNP complex within the
nucleus, therefore modifying its composition through the recruit-
ment of various factors and changes the fate of the viral RNA. We
do not lose sight of the possibility that perturbing the levels of
DDX17 in cells may modulate cellular processes such as RNA
transcription and splicing which in turn affects the process of
HIV-1 packaging.Interestingly, although no noticeable change in the level of
Pr55Gag was observed, over expression of DDX17 DQAD mutants in
HEK293 cells and knockdown of DDX17 in HeLa cells lead to a
dramatic decrease in viral p24 levels, which suggests that DDX17
DQAD mutants inhibit Gag processing. This effect on Gag proces-
sing correlated with a slight diminution of Pr160Gag-Pol (Fig. 5C),
suggesting that the helicase activity of DDX17 is required for
frameshift to occur and for producing optimal ratios of Gag vs
Gag-Pol. Indeed, results of experiments with the frameshift
reporter constructs showed that DDX17 DQAD (L) led to a
signiﬁcant 40% decrease in frameshift efﬁciency (Fig. 6B), which
is expected to result in less production of Pr160Gag-Pol. The
decrease in Pr160Gag-Pol synthesis is expected to reduce viral
protease concentration in the progeny virus particles and conse-
quently, diminish viral Gag processing.Competing interests
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